公开(公告)号：US20110311548A1

公开(公告)日：2011-12-22

申请号：US13163593

申请日：2011-06-17

申请人： Heather Wasserman ,  Timothy L. Carlson ,  Thi-Sau Migone ,  Madhav Devalaraja

发明人： Heather Wasserman ,  Timothy L. Carlson ,  Thi-Sau Migone ,  Madhav Devalaraja

IPC分类号： A61K39/395 ,  A61P11/06 ,  A61P11/00 ,  A61K38/16 ,  A61K39/35

CPC分类号： C07K16/2875 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/76

摘要： The invention relates to methods of preventing, treating, and ameliorating asthma, allergen-induced respiratory symptoms, and/or an allergic or inflammatory condition of the lung or respiratory system in a patient by administering B Lymphocyte Stimulator antagonists. In addition, the invention provides a method of reducing total serum IgE levels in a patient suffering from asthma, and/or an allergic or inflammatory condition of the lung or respiratory system by administering B Lymphocyte Stimulator antagonists. The invention further provides a method of treating, preventing or ameliorating an allergen-induced airway hyper responsiveness or increase in mucus-containing cells and/or mucus accumulation or production in the airway epithelium of a patient by administering B Lymphocyte Stimulator antagonist.

摘要翻译： 本发明涉及通过施用B淋巴细胞刺激物拮抗剂来预防，治疗和改善患者的肺或呼吸系统的哮喘，变应原诱导的呼吸症状和/或过敏性或炎症状态的方法。 此外，本发明提供了通过施用B淋巴细胞刺激物拮抗剂降低患有哮喘和/或肺或呼吸系统的过敏或炎性疾病的患者中的总血清IgE水平的方法。 本发明还提供了一种通过施用B淋巴细胞刺激剂拮抗剂来治疗，预防或改善变应原诱导的气道高反应性或增加含粘液的细胞和/或患者气道上皮中的粘液积聚或产生的方法。

公开(公告)号：US20120014950A1

公开(公告)日：2012-01-19

申请号：US13217023

申请日：2011-08-24

申请人： Thi-Sau Migone ,  Chih-Hung Lo ,  Luke Oh ,  Heather Wasserman ,  Madhav Devalaraja ,  Matthew J. Bernett

发明人： Thi-Sau Migone ,  Chih-Hung Lo ,  Luke Oh ,  Heather Wasserman ,  Madhav Devalaraja ,  Matthew J. Bernett

IPC分类号： A61K39/395 ,  A61P29/00 ,  A61P37/02 ,  A61P19/10 ,  A61P1/00 ,  A61P25/00 ,  A61P37/08 ,  A61P35/00 ,  C07K16/00 ,  A61P19/02

CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention relates to antibodies, antibody fragments, and related molecules that specifically bind to DR3 receptors. Such antibodies have uses, for example, in the prevention, detection, diagnosis, treatment or amelioration of a disease or disorder, especially inflammatory and autoimmune diseases and other immune system disorders, such as Crohn's disease, colitis, Inflammatory Bowel Disease, arthritis, asthma, Multiple Sclerosis, atherosclerosis, and allergic disorders. The invention also relates to nucleic acid molecules encoding anti-DR3 receptor antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially inflammatory or autoimmune disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to DR3 receptor.

摘要翻译： 本发明涉及特异性结合DR3受体的抗体，抗体片段和相关分子。 这样的抗体具有例如用于预防，检测，诊断，治疗或改善疾病或病症，特别是炎症和自身免疫疾病和其他免疫系统疾病如克罗恩病，结肠炎，炎症性肠病，关节炎，哮喘 ，多发性硬化症，动脉粥样硬化和过敏性疾病。 本发明还涉及编码抗DR3受体抗体的核酸分子，含有这些核酸的载体和宿主细胞及其制备方法。 本发明涉及用于预防，检测，诊断，治疗或改善疾病或病症，特别是炎性或自身免疫性疾病的方法和组合物，其包括向动物（优选人）施用有效量的一种或多种抗体或片段或 其变体或相关分子，其特异性结合DR3受体。